Visitors, including guests, contractors and vendors, to any MCW campus are asked to refrain from coming to campus. Badge-access is required to enter any campus building, and cloth face coverings must be worn in all common areas. All MCW-sponsored site visits or gatherings are cancelled.Coronavirus (COVID-19)
Founded in 2016 by Daniel M. Lipinski, DPhil, the Ocular Gene Therapy (OGT) laboratory aims to develop broadly applicable gene-based therapeutics to prevent human blindness arising from neurodegenerative or vascular diseases affecting the retina. Consisting of faculty, students and staff from a diverse range of academic backgrounds, the OGT laboratory takes a highly multidisciplinary and collaborative approach towards research, working with basic science and clinical investigators worldwide to identify novel therapies for currently untreatable conditions that result in vision loss in humans.
Support the Ocular Gene Therapy Laboratory
The OGTL could not exist with without the generosity and support of many foundations, federal agencies and individual donors. Funds donated to the program are used to acquire new equipment and research consumables, to help train students and fellows, to enable the presentation of our research findings at scientific meetings, and to fund positions for support staff.